Compare VICI Properties Inc (VICI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VICI Properties Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? VICI Properties Inc trades at $25.27 (market cap $27.82B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.8× VICI Properties Inc's market cap, and VICI Properties Inc pays a 7.28% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VICI | VRTX | |
|---|---|---|
Market Cap | $27.82B | $134.06B |
Sector | Real Estate | Health |
52-Week High | $33.16 | $557.96 |
52-Week Low | $25.23 | $376.62 |
Enterprise Value | $45.38B | $128.18B |
Dividend Yield | 7.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VICI trades at $25.29, down 0.51% today, with a bearish technical signal from moving averages but oversold RSI readings. The stock offers a high dividend yield above 7%, supported by strong profitability margins (net income margin 67.5% in 2025) and a low P/E of 9.79. Recent corporate actions include a dividend increase to $0.46 per share and the appointment of a new independent director, reflecting steady governance.
Outlook remains positive with a consensus price target of $29.29 (16% upside), driven by stable cash flows and REIT income appeal. Risks include earnings volatility (two recent EPS misses) and acquisition yield pressures. Institutional sentiment is bullish (77% buy ratings), but technical weakness near support at $25 requires monitoring for entry opportunities.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
